Skip to content
logo_IFAPP_crop
  • About
    • Mission & Objectives
    • Definition of Pharmaceutical Medicine
    • PharmaTrain Syllabus
    • Governance
      • The Board of Officers
      • The House of Delegates
      • The General Assembly
    • Constitution
    • History
      • Council of Past Presidents
  • News
    • News & Posts
    • IFAPP World Newsletter Past Editions
  • IFAPP TODAY
  • Working Groups
    • Communication
    • Education and Certification
    • Ethics
    • External Affairs
    • Young Professionals
  • Collaborations & Partners
  • Events
  • Members and Individual Affiliates
  • Publications
  • Course Marketplace

Facilitating submission of post-approval data

By Anna Jurczynska | October 11, 2017

EMA implements new submission form for post-authorisation measures

The European Medicines Agency (EMA) has launched a new form to help marketing authorisation holders submit data generated to satisfy post-authorisation measures(PAMs) for centrally authorised products.

PAMs require marketing authorisation holders (MAHs) to provide additional data on the safety, efficacy or quality of the medicine once it is authorised. They fall into several categories, depending on their legal basis and the type of data to be generated. PAMs can be agreed by the Committee for Medicinal Products for Human Use (CHMP), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee’s (PRAC).

The new form helps to simplify the submission process for PAMs. Upon completing the form, the MAH is automatically informed of the category of PAM and the submission type and code for the eSubmission Gateway. The MAH also receives useful procedural information, including the timetable, the EMA committees involved and the EMA resources assigned.

The easy-to-use form is an integral part of the regulatory submission package and its use is mandatory from 1 September 2017. The form will be part of module 1.0 of the electronic common technical document (eCTD) submission.

This article was originally posted on the U.S. FDA website. 

Posted in Recent News and tagged eCTD, electronic common technical document, ema, European Medicines Agency, PAMs, post-authorisation measures
← FDA improves access to reports of adverse drug reactionsExploring opportunities for collaboration between regulators and healthcare payers →

Recent Posts

  • Introduction to the new EU Clinical Trials Regulation
  • IFAPP TODAY | JANUARY 2023 | NUMBER 30
  • ICPM 2022: Scientists call for cooperative participation of all partners & patients in R&D of new drugs
  • Innovative Options for Course Providers
  • IFAPP TODAY | NOVEMBER/DECEMBER 2022 | NUMBER 29

Categories

  • I am IFAPP
  • Recent News

IFAPP secretariat

Leidsestraatweg 41-D

3443 BP WOERDEN

THE NETHERLANDS

Chamber of Commerce: 30224375

Phone: +31 6 2291 1039

E-mail: secretariat@ifapp.org

Privacy Policy

Cookie Policy

logo_icon

Created By: MDM Creative | ©2019